What is Aegle Therapeutics?
Headquartered in Woburn, Massachusetts, Aegle Therapeutics is a pioneer in the development of extracellular vesicle therapies derived from allogeneic bone marrow-derived mesenchymal stem cells. The company's core technology, exclusively licensed from the University of Miami, allows for the isolation of native EVs without structural modification. These vesicles serve as complex biological delivery vehicles, carrying proteins and nucleic acids that facilitate regenerative healing and immune modulation.
The firm's primary focus is the clinical advancement of AGLE-102, a therapeutic candidate targeting dystrophic epidermolysis bullosa, a debilitating genetic skin disorder. Beyond this lead program, the company's versatile platform holds significant potential for expansion into immunology and protein-deficient disease states, positioning Aegle as a high-value player in the next generation of biopharmaceutical innovation.
How much funding has Aegle Therapeutics raised?
Aegle Therapeutics has raised a total of $13.2M across 3 funding rounds:
Other Financing Round
$4M
Series A
$6.5M
Debt
$456K
Other Financing Round (2020): $4M with participation from DEFTA Healthcare Technologies, DeepWork Capital, New World Angels, Tellus BioVentures, and OceanAzul Partners, LLC
Series A (2020): $6.5M led by DEFTA Healthcare Technologies, DeepWork Capital, New World Angels, and Tellus BioVentures
Debt (2026): $456K, investors not publicly disclosed
Key Investors in Aegle Therapeutics
New World Angels
New World Angels is a Florida-based group of angel investors and venture capitalists that provides seed funding and guidance to qualified early-stage companies.
DeepWork Capital
DeepWork Capital is a venture firm focused on providing early-stage capital and strategic support to high-growth technology and life science companies.
DEFTA Healthcare Technologies
DEFTA Healthcare Technologies is a specialized investment firm dedicated to supporting innovation within the global healthcare and biotechnology sectors.
What's next for Aegle Therapeutics?
With the recent influx of capital, Aegle Therapeutics is well-positioned to accelerate its clinical trial milestones and expand its therapeutic pipeline. The strategic focus will likely remain on the successful execution of the AGLE-102 clinical program, while simultaneously exploring the broader utility of its EV platform in diverse therapeutic areas. As the company transitions further into its clinical-stage lifecycle, the emphasis will shift toward regulatory engagement and potential commercialization pathways for its regenerative medicine portfolio. Investors remain focused on the company's ability to maintain its technological edge in the competitive landscape of cell-free therapies.
See full Aegle Therapeutics company page
